Document 3062
 DOCN  M94A3062
 TI    Course of CD8+CD38+ lymphocyte subset during continuous AZT-ddC
       combination therapy in 25 HIV infected individuals.
 DT    9412
 AU    Holmgren C; Knechten H; Praxiszentrum, Aachen, Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):162 (abstract no. PB0073). Unique
       Identifier : AIDSLINE ICA10/94369513
 AB    INTRODUCTION: The CD8+CD38+ lymphocyte subset is a marker for
       progression of HIV infection but there have been few reports about the
       course of this subset during antiretroviral combination therapy. Thus,
       development of this subset may indicate response to therapy or
       progression of HIV infection. OBJECTIVE: To evaluate the course of
       CD8+CD38+ lymphocyte subset during continuous AZT-ddC combination
       therapy as a possible predictive marker for response to antiretroviral
       AZT-ddC combination therapy or progression of HIV disease. METHODS: In
       an ongoing study CD8+CD38+ lymphocyte subsets of 25 HIV infected
       individuals on AZT-ddC combination therapy were measured in two color
       flow cytometry (Becton Dickinson FACScan and IMK Plus reagent kit).
       Measurements were carried out monthly starting six months before
       beginning the therapy. Patients on therapy were classified as responders
       or non-responders according to further immunological and clinical
       parameters and analysed separately. RESULTS: In about 200 tests in 25
       HIV patients there was no clear evidence for course of CD8+CD38+
       lymphocytes to indicate response to AZT-ddC combination therapy or
       progression of HIV infection. DISCUSSION AND CONCLUSION: Objective and
       practicable routine parameters for response to AZT-ddC combination
       therapy are not satisfactory. Reports about the course of CD8+CD38+
       lymphocyte subsets during this treatment have been scarse. According to
       our results on a small group of patients the CD8+CD38+ lymphocyte subset
       does not seem to be an additional or supplementary predictive marker for
       response to AZT-ddC combination therapy. Further studies on more
       individuals has to be carried out to widen results. Pre-treatment and
       stage of HIVdisease would be interesting points of views to be taken
       into consideration.
 DE    Antigens, CD8/*BLOOD  Antigens, Differentiation/*BLOOD  Drug Therapy,
       Combination  Flow Cytometry  Follow-Up Studies  Human  HIV
       Infections/*DRUG THERAPY/IMMUNOLOGY  Leukocyte Count  T-Lymphocyte
       Subsets/*DRUG EFFECTS/IMMUNOLOGY  Zalcitabine/*ADMINISTRATION & DOSAGE
       Zidovudine/*ADMINISTRATION & DOSAGE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).